Continuity Biosciences announces first-in-human trial for pancreatic cancer
May 21, 2026 | 10:28
Continuity Biosciences started a first-in-human clinical trial of its precision drug delivery platform for pancreatic cancer, now open for enrollment at leading academic medical centers.
Mobile Version